Biosciences
Our researchers in have a rich legacy of collaboration with government agencies and industry partners that improve health outcomes and well-being around the world. SRI Biosciences projects range from high-impact, early-stage research to drug co-development with pharmaceutical and biotech companies.
-
How SRI’s AI technology is changing the way healthcare is delivered
Governments around the world have encouraged healthcare providers to utilize Telehealth to safely care for patients
-
SRI awarded $107 million NIAID-DAIDS contract to provide preclinical services for HIV therapeutics
SRI International has been awarded a contract from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and the Division of AIDS to support research and product development for human immunodeficiency virus (HIV), Mycobacterium tuberculosis (MTB) complex, and hepatitis B and C viruses (HBV/HCV).
-
SRI International awarded $40 million NICHD contract for pre-clinical development of new male and female contraceptive products
SRI International has been awarded a Biological Testing Facility contract to complete discovery and preclinical development of new contraceptive compounds.
-
Solving for sleep
SRI’s Human Sleep Research Program is conducting groundbreaking research to address modern sleep challenges
-
SRI International awarded $4.3M from DARPA to create rapid response therapeutic manufacturing system
Extension of SynFini synthetic chemistry platform could accelerate availability ofnew treatments in pandemic and other emergency health situations MENLO PARK, Calif. – October 6, 2020 – SRI International has been awarded $4.3 million from the Defense Advanced Research Projects Agency (DARPA) to create ProSyn™, an agile, rapidly deployable extension of SynFini™, SRI’s fully automated synthetic…
-
SRI receives NSF grant to create new viral classification system
SRI International has been awarded a National Science Foundation (NSF) grant through the Grants for Rapid Response (RAPID) program. RAPID is a mechanism used by the NSF to provide funds for urgent research that addresses unexpected disasters or events such as the COVID-19 pandemic. SRI scientists will use the RAPID grant to develop a first-of-its-kind…
-
SRI research scientists discuss new opportunities for large-scale data collection through consumer sleep technology
Consumer sleep technology (CST) is a fast-paced industry, and little is known about the accuracy and reliability of consumer sleep-tracking devices
-
What if you gave cancer the measles?
SRI has created a novel platform that could significantly expand the benefit of immunotherapies by “infecting” cancer cells
-
SRI International Awarded Contract Worth Up to $100M from National Institute of Allergy and Infectious Diseases for Radiation/Nuclear Medical Countermeasures
Grant extends SRI’s long history of collaborations with the National Institutes of Health.
-
Developing the next generation of PCR diagnostics for point-of-contact screening
SRI International investigator awarded National Science Foundation grant for development of a revolutionary point of contact diagnostic for infectious diseases The current world-wide COVID-19 pandemic underscores the need for rapid and widespread screening for emerging infectious agents. As emerging infectious diseases can spread rapidly, government agencies have made developing detection technologies a priority. To explore…
-
Nathan Collins talks about the SynFini™ automated chemistry platform (Part 1)
Nathan Collins discusses how the SynFini automated chemistry platform is accelerating drug development and discovery. Learn more about SynFini at: https://www.sri.com/case-studies/synfini. Nathan Collins is the Chief Strategy Officer of SRI Biosciences in Menlo Park, CA. In part one of this episode of The Dish TV they discuss the processes and problems of new drug discovery…
-
Nathan Collins talks about integrating AI with the SynFini™ Platform (Part 2)
Nathan Collins discusses how integrating AI with the SynFini automated chemistry platform is poised to shape the future of drug discovery and development. Learn more about SynFini at: https://www.sri.com/case-studies/synfini Nathan Collins is the Chief Strategy Officer of SRI Biosciences in Menlo Park, CA. In part two of this episode of The Dish TV they discuss…